Addressing Social Vulnerabilities in Cardiovascular Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03613064 |
Recruitment Status :
Not yet recruiting
First Posted : August 2, 2018
Last Update Posted : December 17, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Congestive Heart Failure Ischemic Heart Disease Acute Myocardial Infarction Coronary Artery Disease | Other: Socially Enhanced Transitional Care Intervention | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Health Services Research |
Official Title: | Addressing Social Vulnerabilities to Prevent Hospital Readmissions in Adults With Cardiovascular Disease |
Estimated Study Start Date : | June 2020 |
Estimated Primary Completion Date : | May 2022 |
Estimated Study Completion Date : | May 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Congestive Heart Failure (CHF)
The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
|
Other: Socially Enhanced Transitional Care Intervention
Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites. |
Experimental: Ischemic Heart Disease (IHD)
The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
|
Other: Socially Enhanced Transitional Care Intervention
Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites. |
- Reach of the intervention ('R' of the RE-AIM Implementation Science Framework) [ Time Frame: Up to 12 months ]Proportion of individuals enrolled, of those who are eligible for the intervention
- Effectiveness of the intervention ('E' of the RE-AIM Implementation Science Framework) - Referrals [ Time Frame: Up to 12 months ]Proportion of referrals to community-based service programs that are completed, of referrals that are sent. 'Completed' will be defined as individuals arriving in-person at a community-based service program after a referral is placed.
- Effectiveness of the intervention ('E' of the RE-AIM Implementation Science Framework) - Health Services Utilization [ Time Frame: Up to 12 months ]Changes in acute health services use (composite of emergency department visits, hospitalizations) before and after the intervention using interrupted time series
- Effectiveness of the intervention ('E' of the RE-AIM Implementation Science Framework) - Satisfaction [ Time Frame: Up to 12 months ]Patient satisfaction with the intervention program using brief verbal questionnaires
- Adoption of the intervention ('A' of the RE-AIM Implementation Science Framework) [ Time Frame: Up to 12 months ]Number of community organizations active in referral and information exchange intervention
- Implementation of the intervention ('I' of the RE-AIM Implementation Science Framework) [ Time Frame: Up to 12 months ]Acceptability, feasibility, and fidelity to intervention, ascertained through semi-structured interviews of research subjects, discharge planners, case managers, community program directors with thematic analysis of interview findings. We will ascertain perspectives on all three constructs during interviews and identify common themes across constructs to understand barriers and facilitators to implementation in aggregate
- Readmission rate [ Time Frame: Up to 12 months ]Rate of 30-day readmissions among research subjects. We anticipate that we will be underpowered to detect a difference with our limited planned enrollment during this pilot feasibility study

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 120 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients hospitalized with CHF and IHD at high-risk for readmission
Exclusion Criteria:
- none

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03613064
Contact: Oanh K Nguyen, MD | 415-206-3755 | Oanh.Nguyen@ucsf.edu |
Principal Investigator: | Oanh K Nguyen, MD | University of California, San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT03613064 |
Other Study ID Numbers: |
STU 022016-033 1K23HL133441 ( U.S. NIH Grant/Contract ) |
First Posted: | August 2, 2018 Key Record Dates |
Last Update Posted: | December 17, 2019 |
Last Verified: | December 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Failure Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Myocardial Infarction Heart Diseases Infarction |
Ischemia Pathologic Processes Necrosis Coronary Disease Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |